License agreement with Tata Chemicals

OptiBiotix Health PLC

23 October 2023

 

OptiBiotix Health plc

("OptiBiotix" or the "Company")

License agreement with Tata Chemicals

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces that it has reached an agreement with Tata Chemicals Limited ("Tata Chemicals") to incorporate its proprietary Fossence^® into SlimBiome^® and LeanBiome^® for the Indian market.

The agreement incorporates Tata's Fossence^®, a proprietary short chain fructo-oligosaccharide ("FOS") into OptiBiotix's SlimBiome^® and LeanBiome^® products for the Indian market. Fossence^® will be a direct replacement for the FOS used in SlimBiome^® in other markets and brings scientific substantiation of health benefits shown by  FOS in the Indian market (see  Explore - Brochures, Whitepapers, Concept Notes & More | Tata NQ). Tata Chemicals have approved the use of the Fossence^® logo on products containing SlimBiome^® in India bringing a branded ingredient from a well-known and trusted source to the attention of Indian consumers.

Tata Chemicals is a global science company active in industrial chemicals, food and nutrition (Tata NQ), and agriculture listed on the Indian stock Exchange. It is part of the Tata Group which employs over one million people with annual revenues in 2022 of $300billion.

Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to report this agreement with Tata Chemicals which creates the opportunity to bring products containing Tatas proprietary Fossence^® in SlimBiome^® and LeanBiome^® to the Indian market. Tata Chemicals is one of India's leading suppliers of food ingredients with many well-known and respected brands. Fossence's® established health benefits with Indian consumers and its trusted brand combined with SlimBiome's® strong science, clinical studies, and excellent customer reviews will help reduce hunger and food cravings to support the weight management efforts of India's 135 million obese men and women."

For further information, please contact:

OptiBiotix Health plc		www.optibiotix.com
Neil Davidson, Chairman	Contact via Walbrook below
Stephen O'Hara, Chief Executive
Cairn Financial Advisers LLP (NOMAD)		Tel: [phone]
Liam Murray / Jo Turner / Ludovico Lazzaretti
Peterhouse Capital Limited (Broker)		Tel: [phone]
Duncan Vasey / Lucy Williams
Walbrook PR Ltd		Mob: [phone]
Anna Dunphy

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 

 

END